Sven-Arne Jansson1, Helena Backman2, Maria Andersson3, Gunilla Telg4, Anne Lindberg5, Caroline Stridsman6, Bo Lundbäck7, Eva Rönmark8. 1. Department of Public Health and Clinical Medicine, Section of Sustainable Health, The OLIN Unit, Umeå University, Umeå, Sweden. Electronic address: sven-arne.jansson@umu.se. 2. Department of Public Health and Clinical Medicine, Section of Sustainable Health, The OLIN Unit, Umeå University, Umeå, Sweden. Electronic address: helena.backman@norrbotten.se. 3. AstraZeneca Nordic-Baltic, Södertälje, Sweden. Electronic address: maria.a.andersson@astrazeneca.com. 4. AstraZeneca Nordic-Baltic, Södertälje, Sweden. Electronic address: gunilla.telg@astrazeneca.com. 5. Department of Public Health and Clinical Medicine, Division of Medicine, Umeå University, Umeå, Sweden. Electronic address: anne.lindberg@algmed.se. 6. Department of Health Sciences, Luleå University of Technology, Luleå, Sweden. Electronic address: caroline.stridsman@norrbotten.se. 7. Krefting Research Centre, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden. Electronic address: bo.lundback@gu.se. 8. Department of Public Health and Clinical Medicine, Section of Sustainable Health, The OLIN Unit, Umeå University, Umeå, Sweden. Electronic address: eva.ronmark@norrbotten.se.
Abstract
BACKGROUND: The aim of the present study was to estimate the societal costs and the key cost drivers for patients with severe asthma in Sweden. In addition, health-related quality of life (HRQOL) and morbidity of patients with severe asthma is described. METHODS: The study population comprised adults with severe asthma recruited from a large asthma cohort within the Obstructive Lung Disease in Northern Sweden (OLIN) studies. During 2017, patients were interviewed quarterly over telephone regarding their resource utilization and productivity losses. RESULTS: Estimated mean annual asthma-related costs per patient with severe asthma amounted to €6,500, of which approximately €2400 and €4100 were direct and indirect costs, respectively. The main cost drivers for direct costs were hospitalizations followed by drugs: approximately €1000 and €800, respectively. Patients on treatment with regular oral corticosteroids (OCS) had greater direct costs compared with those without regular OCS treatment. Co-morbid conditions were common and the costs were substantial also for co-morbid conditions, with a total cost of approximately €4200. The OCS group had significantly lower HRQOL compared to the non-OCS group. CONCLUSIONS: The societal costs due to severe asthma were substantial. Costs for co-morbid conditions contributed substantially to both direct and indirect costs. The direct costs were significantly higher in the maintenance OCS-group compared to the non-maintenance OCS-group. These results indicate a need for improved management and treatment regimens for patients with severe asthma.
BACKGROUND: The aim of the present study was to estimate the societal costs and the key cost drivers for patients with severe asthma in Sweden. In addition, health-related quality of life (HRQOL) and morbidity of patients with severe asthma is described. METHODS: The study population comprised adults with severe asthma recruited from a large asthma cohort within the Obstructive Lung Disease in Northern Sweden (OLIN) studies. During 2017, patients were interviewed quarterly over telephone regarding their resource utilization and productivity losses. RESULTS: Estimated mean annual asthma-related costs per patient with severe asthma amounted to €6,500, of which approximately €2400 and €4100 were direct and indirect costs, respectively. The main cost drivers for direct costs were hospitalizations followed by drugs: approximately €1000 and €800, respectively. Patients on treatment with regular oral corticosteroids (OCS) had greater direct costs compared with those without regular OCS treatment. Co-morbid conditions were common and the costs were substantial also for co-morbid conditions, with a total cost of approximately €4200. The OCS group had significantly lower HRQOL compared to the non-OCS group. CONCLUSIONS: The societal costs due to severe asthma were substantial. Costs for co-morbid conditions contributed substantially to both direct and indirect costs. The direct costs were significantly higher in the maintenance OCS-group compared to the non-maintenance OCS-group. These results indicate a need for improved management and treatment regimens for patients with severe asthma.
Authors: C Stridsman; J R Konradsen; L Vanfleteren; C Pedroletti; J Binnmyr; P Edfelt; K Fjällman Schärberg; Y Sjöö; F Nyberg; A Lindberg; A Tunsäter; A Ekberg-Jansson Journal: Eur Clin Respir J Date: 2020-10-23
Authors: Barbara Putman; Louise Coucke; Anna Vanoverschelde; Els Mehuys; Lies Lahousse Journal: BMC Health Serv Res Date: 2022-01-26 Impact factor: 2.655
Authors: Christer Janson; Leif Bjermer; Lauri Lehtimäki; Hannu Kankaanranta; Jussi Karjalainen; Alan Altraja; Valentyna Yasinska; Bernt Aarli; Madeleine Rådinger; Johan Hellgren; Magnus Lofdahl; Peter H Howarth; Celeste Porsbjerg Journal: Eur Clin Respir J Date: 2022-03-02
Authors: Evalyne M Jansen; Susanne J van de Hei; Boudewijn J H Dierick; Huib A M Kerstjens; Janwillem W H Kocks; Job F M van Boven Journal: J Thorac Dis Date: 2021-06 Impact factor: 2.895